In this lecture, we will explore the adverse effects associated with ACE inhibitors, including their underlying mechanisms and at-risk populations. While ACEIs are generally well tolerated and even metabolically beneficial, they may lead to complications such as hypotension, dry cough, hyperkalemia, acute renal failure, angioedema, fetopathic effects, and rare hematologic or taste-related disturbances. Understanding the pathogenesis and clinical context of these adverse effects is essential for risk mitigation and therapeutic decision-making.
Learning Objectives
By the end of this session, participants will be able to:
Explain the mechanisms behind common ACEI adverse effects such as hypotension, cough, hyperkalemia, and acute kidney injury.
Identify clinical risk factors that increase susceptibility to ACE inhibitor complications (e.g., renal stenosis, diabetes, polypharmacy, pregnancy).
Discuss the management strategies, including when to reduce dose, discontinue therapy, or switch to ARBs.
Recognize rare but serious effects, including angioedema, fetopathy, rash, dysgeusia, neutropenia.
Counsel patients on safety, particularly women of childbearing potential and those with renal, cardiovascular, or immunologic vulnerabilities.
Learning Objectives
By the end of this session, participants will be able to:
Explain the mechanisms behind common ACEI adverse effects such as hypotension, cough, hyperkalemia, and acute kidney injury.
Identify clinical risk factors that increase susceptibility to ACE inhibitor complications (e.g., renal stenosis, diabetes, polypharmacy, pregnancy).
Discuss the management strategies, including when to reduce dose, discontinue therapy, or switch to ARBs.
Recognize rare but serious effects, including angioedema, fetopathy, rash, dysgeusia, neutropenia.
Counsel patients on safety, particularly women of childbearing potential and those with renal, cardiovascular, or immunologic vulnerabilities.
Write A New Comment
0 Comments